Chemical modification of an active drug with promoiety to a prodrug ("prodrugging") is a way to improve the pharmacokinetic characteristics of an active drug in the body; however, no kinetic principles have been proposed to design orally effective prodrugs to overcome biological membrane barriers. Therefore, based on a previously reported kinetic model of drug absorption [Mizuma et al., J Pharm. Sci. 85, 854 (1996)], conditional equations for the kinetic strategy of prodrugging were derived. Conditional equations contain terms of uptake (influx) and efflux transport of the prodrug and drug, and the metabolism of the prodrug to drug. Thereby, kinetic classification and criteria for effective membrane-permeable prodrugs are shown as a decision tree with conditional equations. The first point in the kinetic classification and criteria is the uptake process; second, the efflux process is vetted; finally, the metabolic process is elucidated. In some cases, metabolism is not a factor in the better absorption of prodrugs than active drugs. Experiments corresponding to particular processes were proposed, and are applicable to the design of prodrugs not only for intestinal absorption, but also for biological membrane permeation.
Introduction
Chemical modification of an active drug with promoiety to a prodrug is a way to improve the pharmacokinetic characteristics of active drugs in the body. There are several types of prodrugs, which have purposes such as increased solubility, targeting a specific organ/tissue, improved membrane permeability and so on. Characteristics to be considered in the design of prodrugs to improve the intestinal absorption of active drugs is that lipophilic promoiety is bound to active drugs to give high permeability to the gastrointestinal membrane by passive diffusion, for example, bacampicillin (ampicillin prodrug), and that functional promoiety is bound to active drugs to be transported by, for example, valaciclovir (acyclovir prodrug).
However, no kinetic principles have been proposed to design orally active prodrugs to improve gastrointestinal absorption; therefore, in the present paper, this was kinetically studied by deriving theoretical equations, addressing the kinetic aspect to rationally design orally active prodrugs. Kinetic classification and criteria for effectively absorbed (membrane-permeable) prodrugs are proposed.
Theory

Absorption process of prodrugs
The absorption process of prodrugs is shown in Figure 1 . A prodrug on the mucosal side is transported into intestinal tissue, and is partly metabolized to an (active) drug. Prodrugs that escape Cp,muc, Cp,ice and Cp,ser represent prodrug concentrations on the mucosal side, intestinal tissue and serosal side, respectively; fp,muc, fp,ice and fp,ser represent the unbound fraction of the prodrug on the mucosal side, intestinal tissue and serosal side, respectively. Cd,muc, Cd,ice and Cd,ser represent drug concentrations on the mucosal side, intestinal tissue and serosal side, respectively; fd,muc, fd,ice and fd,ser represent the unbound fraction of the drug on the mucosal side, intestinal tissue and serosal side, respectively. CLp,m-i, CLp,i-m, CLp,i-s, CLmet,int and Q are transport clearance from the mucosal side into intestinal cells, transport clearance from intestinal cells to the mucosal side, transport clearance from intestinal cells to the serosal side, the intrinsic clearance of metabolism and mucosal blood flow, respectively. CLd,m-i, CLd,i-m and CLd,i-s are transport clearance from the mucosal side into intestinal cells, transport clearance from intestinal cells to the mucosal side, and transport clearance from intestinal cells to the serosal side, respectively. the metabolism to become active appear in the vascular space as prodrugs. This process is called Process PP. The (active) drug that forms from the prodrug in the intestinal tissue appears in the vascular space. The process is called Process PD.
Derivation of kinetic equations
The absorption clearance of the prodrug in Process PP (CLpp,abs) is expressed as follows, based on a previous report [1] :
where Cp,muc, fp,muc, CLp,m-i, CLp,i-s, CLp,i-m and CLmet,int are the mucosal concentration, mucosal unbound fraction, transport clearance from mucosal to intestinal tissue, transport clearance from intestinal tissue to the serosal side, transport clearance from intestinal tissue to the mucosal side and intrinsic metabolism clearance of prodrug, respectively. Absorption is assumed to be not blood-flow-rate limited.
Absorption clearance of the prodrug in Process PD (CLpd,abs) is derived as follows:
where CLd,i-s and CLd,i-m are transport clearance from intestinal tissue to the serosal side and transport clearance from intestinal tissue to the mucosal side for a drug, respectively. Absorption is assumed to be not blood-flow-rate limited.
Total absorption clearance for a prodrug (CLpp+pd,abs), which is the sum of Process PP and Process PD, is expressed by:
CLpp+pd,abs = CLpp,abs + CLpd,abs
Absorption process and kinetic equation of drugs
The absorption process of drugs is shown in Fig. 1 . The absorption clearance of drugs (CLdd,abs) is expressed as follows, based on a previous report [1] :
where CLd,m-i and fd,muc are transport clearance from the mucosal side to intestinal tissue and the mucosal unbound fraction of a drug, respectively.
Pharmacokinetic requirement for effective (useful) prodrugs
The pharmacokinetic requirement for effective absorption of prodrugs is:
CLpp+pd,abs / CLdd,abs > 1
Eq. (7) When it is "effective" that CLpp+pd,abs is more than IR (≥1) times CLdd,abs, Eq. (8) is derived.
CLpp+pd,abs / CLdd,abs > IR Eq. (8) Thus, IR is a minimum improvement requirement for an "effective" prodrug, and is targeted based on the relationship between fraction absorbed (Fa) and absorption clearance (CLabs) (or permeability coefficient), as shown in Figure 2 (or as reported by Artursson and Karlsson [2] ). The relationship between the fraction absorbed and absorption clearance can be obtained based on your own experimental data of absorption clearance or a database. Eq. (9) is the conditional equation for effective prodrugs. 
Classification and criteria of a produg
Three cases are shown in Scheme 1 as the first step in classification, which is based on the comparison of prodrug and drug uptake into intestinal tissue (CLp,m-i fp,muc versus CLd,m-i fd,muc IR). Effective when satisfying Eq. 9
Case IIIa Case IIIb
Yes No
Ineffective, irrespective of metabolism data Scheme 1. Kinetic classification and criteria for effective membrane-permeable prodrugs.
Case I
When CLp,m-i fp,muc > CLd,m-i fd,muc IR, the second classification can be as follows. Case Ia. When satisfying Eq. (10), the prodrug is effective, irrespective of prodrug to drug metabolism.
Strategic considerations for the kinetics of prodrugs and drugs 4.1 Effective prodrug and IR
When prodrugs and drugs are transported exclusively by passive diffusion, lipophilicity is a crucial factor in intestinal absorption, as in Case Ia. Successful prodrugs, which have been developed and used, may be categorized as Case Ia; however, if a prodrug or drug is in part transported by a transporter, it is categorized as other cases. For example, valaciclovir (prodrug of acyclovir) is transported from the mucosal side by PEPT1 across the brush border membrane [3] . The oral bioavailability of acyclovir, of which a small fraction is metabolized in the liver, is 15-30%, whereas the oral bioavailability of valaciclovir is 54.2% [3] . This indicates that the absorption of acyclovir increased 1.8-3.6 times after prodrugging. A successful prodrug, valaciclovir, is similar to Case I and either Case Ia or Case Ib, and the IR satisfies the relationship between 54.2% of fraction absorbed and the improved absorption clearance.
On the other hand, an unsuccessful prodrug of ME3277 has been reported [4] . After intravenous administration, ME3277 was eliminated primarily in urine in the unchanged form. The oral bioavailability of ME3277 was approximately 1%, whereas after oral administration of ME3229 (prodrug of ME3277), 10% of dose was absorbed [4] . This indicates that the absorption of ME3277 increased approximately 10 times after prodrugging. ME3229 (prodrug of ME3277) is more lipophilic than the active drug (ME3277), and the uptake clearance of ME3229 was comparable to that of warfarin [4] . This suggests that the uptake clearance of ME3229 was higher than that of ME3277, although the uptake clearance of ME3277 was not described in the paper. Therefore, when IR is unity, the uptake experiment data satisfy CLp,m-i fp,muc > CLd,m-i fd,muc x 1, and ME3229 is categorized as Case I according to the first classification. Since ME3277 is transported by a transporter from intestinal tissue to the mucosal side [4] , CLd,i-m is much larger than CLd,i-s; therefore, CLp,i-s/CLp,i-m is larger than CLd,i-s/CLd,i-m when CLp,i-s is almost equal to CLp,i-m. Thus, ME3229 is an "effective" prodrug categorized into Case Ia when IR is unity.
However, it was reported that ME3229 was not "effective" as an orally active prodrug, although ME3277 absorption increased from 1% to 10% of the dose by prodrugging [4] . If 50% absorption is "effective", IR, which is estimated based on the relationship between the fraction absorbed and absorption clearance, should be much higher than unity. In this case, ME3229 may be categorized into Case III based on uptake data. In the second classification, ME3229 is categorized as Case IIIa based on efflux data that CLd,i-m is much larger than CLd,i-s. ME3229 had to satisfy Eq. (9); thus indicating that the effectiveness of a prodrug depends on how high the absorbed fraction needs to be.
Metabolism of prodrug to drug
In Case Ia, Case IIa, Case IIb and Case IIIb, the absorption effectiveness of a prodrug is independent of the metabolic process. The absorption of a prodrug is effective in Case Ia and Case IIa, whereas a prodrug is ineffective in Case IIb and Case IIIb. This indicates that only membrane transport is a crucial factor in these cases; therefore, if these conditions are true of a novel prodrug, the next study should be a transport experiment. This is a valuable finding because it does not involve the metabolic enzyme, which is one of the major problems of species difference in the prediction of pharmacokinetics in humans but, in other cases, metabolic activity influences the absorption effectiveness of prodrugs.
Next target in transport study
As described above, the kinetic classification and criteria for effective membrane-permeable prodrugs shown in Scheme 1 suggest guidelines for the rational design of orally effective prodrugs. Recently, drug influx from the mucosal side to intestinal tissue and drug efflux from intestinal tissue to the mucosal side have been targeted primarily in drug absorption studies. In contrast, this paper clarified that studies not only on these processes, but also on transport from intestinal tissue (cells) to the vascular space (serosal side) are required to rationally develop prodrugs. In addition, the classification in this paper is not limited to intestinal absorption, but can be extended to drug permeation of a biological barrier, such as tissues.
Conclusions
Kinetic classification and criteria for effective membrane-permeable prodrugs are proposed as a decision tree with conditional equations. The uptake rate of prodrugs from the mucosal side to intestinal tissue is important for better absorption than active drugs, but also relative permeability from intestinal tissue to the mucosal and serosal sides for prodrugs and active drugs is significant.
In addition, in some cases, metabolism is not a factor in the better absorption of prodrugs than active drugs.
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